Back to Journals » Clinical Ophthalmology » Anti-VEGF Therapies in Retinal Disorders: Recent Advances, Biosimilars, and Future Directions
Clinical Ophthalmology
- View all (6414)
- Volume 20, 2026 (222)
- Volume 19, 2025 (481)
- Volume 18, 2024 (412)
- Volume 17, 2023 (407)
- Volume 16, 2022 (424)
- Volume 15, 2021 (525)
- Volume 14, 2020 (503)
- Volume 13, 2019 (309)
- Volume 12, 2018 (329)
- Volume 11, 2017 (293)
- Volume 10, 2016 (317)
- Volume 9, 2015 (323)
- Volume 8, 2014 (358)
- Volume 7, 2013 (344)
- Volume 6, 2012 (324)
- Volume 5, 2011 (296)
- Volume 4, 2010 (225)
- Volume 3, 2009 (101)
- Volume 2, 2008 (142)
- Volume 1, 2007 (78)
Journal Sections:
Journal Articles:
- Emerging Trends in Digital Ophthalmology and Social Media (5)
- Comprehensive Management of Complex Cataracts: Surgical Innovations and Postoperative Strategies (2)
- Anti-VEGF Therapies in Retinal Disorders: Recent Advances, Biosimilars, and Future Directions (6)
- Translating Science to Practice in Uveitis: A Step-by-Step Clinical Guide Across the Disease (2)
- The Choroid in Health and Disease (1)
- Advances in Intraocular Lenses (3)
- Climate Change and Ophthalmology (4)
- OCT Biomarkers of Macular Disorders: From Theory to Practice (4)
- Recent Advances in Refractive Surgery (14)
- Creating of a Uniform Cornea Using Contoura (3)
Anti-VEGF Therapies in Retinal Disorders: Recent Advances, Biosimilars, and Future Directions
The advent of anti-VEGF (vascular endothelial growth factor) therapies has revolutionized the management of retinal disorders, offering significant improvements in vision and quality of life for millions of patients worldwide. These therapies, initially developed for conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME), have set new standards in ophthalmic care by effectively controlling disease progression and reducing the need for more invasive treatments.
Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions
Sheth JU
Clinical Ophthalmology 2026, 20:603279
Published Date: 1 April 2026
Intravitreal Bevacizumab Alone Vs Combined With Topical Timolol-Dorzolamide or Dorzolamide for Diabetic Macular Edema: A Systematic Review and Meta-Analysis
Hubayni RA, Qedair J, Bukhari ZM, Alsudais AS, Badghaish OS, Bawazir RO, AlQahtani AS, Almarzouki H
Clinical Ophthalmology 2025, 19:1007-1019
Published Date: 22 March 2025
Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
Aljuhani HS, Hubayni RA, Qedair J, Bukhari ZM, Alzahrani A, Bawazir RO, Badghaish OS, Alqahtani F
Clinical Ophthalmology 2025, 19:1911-1918
Published Date: 19 June 2025
Quantitative Assessment of En‑face OCT‑Derived Minimum Intensity Fluid Changes Following Ranibizumab Biosimilar Therapy in Macular Neovascularization Secondary to nAMD and PCV
Sheth JU, Bhopalka AK, Meshram B, Karande S
Clinical Ophthalmology 2025, 19:2505-2512
Published Date: 29 July 2025
Discordance Among Patients and Ophthalmologists Regarding the Burden of Intravitreal Injections
Robinson K, Cooper SJ, Persaud S, Frederick JL, Singh RP
Clinical Ophthalmology 2025, 19:2637-2645
Published Date: 8 August 2025
Additional Effects of Faricimab in Aflibercept Low-Responders: Retinal Morphology and Function in Eyes with Neovascular Age Related Macular Degeneration Following a Switch Between Two Anti-VEGF Agents
Rothbächer J, Khalil H, Eidherr M, Bolz M
Clinical Ophthalmology 2025, 19:3145-3152
Published Date: 3 September 2025